The present invention relates to methods of treating Lewy body dementia, multi-system atrophy or pure autonomic failure in a subject in need thereof. Also provided are compositions for treating Lewy body dementia, multi-system atrophy or pure autonomic failure.

This invention relates to a method of producing mixtures of various human milk oligosaccharides (HMOs) with unique HMO blend profiles, consisting predominantly of LNFP-I and LNT and of other HMOs in less significant amounts. The less abundant HMOs might be 2-FL, LNT-II or DFL. The strategies for achieving specific HMO blends include strain engineering and fermentation methods.

The present invention relates to primarily genetically modified microorganisms for in vivo synthesis of lacto-N-tetrose (LNT) and lacto-N-neotetrose (LNnT), and their fucosylated derivatives, and to uses of such microorganisms in methods of producing lacto-N-tetrose and lacto-N-neotetrose, and their fucosylated derivatives.